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Abstract. 14 
Antibiotic resistance is one of the main problems concerning public health or clinical practice. 15 
Antimicrobial peptides appear as good candidates for the development of new therapeutic 16 
drugs. In this study we de novo designed a group of cationic antimicrobial peptides, analyzed 17 
its physicochemical properties, including its structure by circular dichroism and studied its 18 
antimicrobial properties against a panel of clinical isolates expressing different mechanisms of 19 
resistance. Three cationic alpha helical peptides exhibited antimicrobial activity comparable to, 20 
or even better than the comparator omiganan (MBI‑226).  21 
 22 
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Introduction  25 
Antimicrobial peptides (AMPs) are naturally occurring molecules of the innate immune system 26 
that play an important role in the host defense of animals and plants [1]. In recent years, 27 
natural or designed AMPs have attracted considerable interest as potential candidates for the 28 
development of novel antibiotics [2-3]. The main reason for this interest is that its particular 29 
mechanism of action is unlikely to induce drug resistance, in part because resistance against 30 
AMPs cannot be selected without bacterial cell wall undergoing profound structural changes 31 
[4]. However, pathogens can eventually respond to AMPs reducing the negative charge of their 32 
cell envelope with specific surface modifications and subvert mechanisms of AMPs [5]. 33 
Bacteria are capable of adapting and resisting AMPs, through the  production of peptidases 34 
and proteases that degrade antimicrobial peptides, and the production of compounds that 35 
inhibit the action of AMPs [6] 36 
The broad activity spectrum and the relative selectivity towards microbial membranes are also 37 
two important features that drive the interest of researchers on AMPs as new antibiotic 38 
molecules.   39 
The cationic AMP omiganan (MBI‑226), an analogue of indolicidin, is one of the most studied 40 
AMPs and it has recently finished Phase II trials (ClinicalTrials.gov identifier: NCT00608959). 41 
Omiganan showed activity against gram-positive and gram-negative bacteria but also Candida 42 
spp. isolates [7-8]. Therefore, the objectives of this work were to design a group of new 43 
peptide sequences, and analyze their physicochemical properties and antimicrobial activities 44 
against 82 bacterial strains, including wild type and drug resistant clinical isolates. Omiganan 45 
was used in this study as comparator for these peptides. 46 
 47 
Materials and methods 48 
Peptides design and synthesis  49 
The sequences were designed using a combined rational and computer assisted approach. 50 
Cationic alpha helical peptides were designed identifying short putative active regions from 51 
AMP databases. Then, these regions were combined or modified in order to have cationic 52 
sequences with different physicochemical parameters, like alpha helix content and 53 
hydrophobicity. For this purpose we used multiple alignment tools and simulators of 54 
physicochemical properties like ClustalX, HeliQuest [9] and HydroMCalc [10]. We established 55 
specific amino acid positions and identified functionally relevant motifs in natural or designed 56 
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peptides. Considering all these diverse parameters, a group of peptides was synthesized with 57 
or without C terminus amidation. The purity grade of all peptides was >95% by HPLC 58 
(GenScript Co., Piscataway, NJ 08854, USA). The peptide sequences: Peptide 1: 59 
WPKWWKWKRRWGRKKAKKRRG; peptide2: GLLKKWLKKWKEFKRIVGY; peptide3: 60 
FGKEKKAWWRRRKWLK ;  peptide5: RIVQRIKKWLLKWKKLGY. 61 
 62 
Bacterial Strains 63 
The panel analyzed  included 82 previously well characterized isolates collected at the National 64 
Reference Laboratory (INEI) with different mechanisms of resistance: 39 Gram-positive (vanA, 65 
vanB, vanC, mecA, ermA, ermC, msrA, lnuA genes) and 43 Gram-negative bacteria (blaVIM, 66 
blaIMP, blaSPM, blaKPC-2, blaOXA-23, blaOXA-58, blaCTX-M-2, blaPER-2, blaGES, blaVEB-1, blaTEM-1, blaCMY, blaCIT, 67 
blaSHV-1, blaOXA-9). The panel includes P. aeruginosa ATCC27853, E. coli ATCC25922, S. aureus 68 
ATCC29213, E. faecalis ATCC51299 and E. faecalis ATCC29212 reference strains.  69 
Antimicrobial activity 70 
Minimal inhibitory concentration was determined by standard microdilution assay according to 71 
CLSI recommendations [11], using Mueller Hinton Broth (DIFCO) supplemented with Ca
2+
 (20-72 
25mg/L) and Mg
2+
 (10-12.5mg/L). Omiganan® was used as comparator.  73 
Hemolytic assay  74 
The citotoxic activity of the peptides was evaluated according to the method described 75 
previously [12]. Briefly, a volume of heparinized human whole blood was diluted 3x in 76 
phosphate-buffered saline and then centrifuged 10 min. at 1500 rpm. This procedure was 77 
repeated three times.  The cellular pellet was resuspended in phosphate-buffered saline to a 78 
final dilution of 10% (v/v). The stock cell suspension was further diluted to about 0.5% (v/v). 79 
Peptides were then added at different concentrations and incubated at 37 ºC for 30 min. 80 
Afterwards, tubes were centrifuged and the absorbance of the supernatant was measured at 81 
550 nm. The percentage of lysis was then calculated relative to 0% lysis with buffer and 100% 82 
lysis with water. The absorbance measurement was repeated three times, and the averaged 83 
values were used. 84 
 Circular dichroism in the far UV 85 
We studied the secondary structure content by circular dichroism spectroscopy in the far UV, 86 
using a JASCO J computer 810 (Jasco Corp., Tokyo, Japan) acid calibrated with (+) 10 87 
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camphorsulfonic acid. The measurements were performed under nitrogen gas flow of 8 l/h at 88 
a temperature of 20 °C, controlled by a Peltier system (JASCO). 89 
Spectra were recorded between 185 and 320 nm, using a 0.1 cm cell path length. The peptide 90 
concentrations were 40 uM, dissolved in sodium phosphate buffer pH 7.0 or 10 mM in the 91 
same buffer with sodium dodecyl sulphate (SDS) 10 mM. The sensitivity was 100 millidegrees. 92 
We used a scan speed of 50 nm/min, a response time of 1 s and a bandwidth of 1 nm. We 93 
performed an average of five assays for each sample spectra. The average absorption was 94 
corrected by buffer and then baseline to zero using the average of readings between 290 and 95 
320 nm. Finally, the data were smoothed using a Golay polynomial Savizky fourth grade, with a 96 
window of ten points. The spectra were converted to molar ellipticity residue half by using the 97 
relationship:  , where [θ] is the molar ellipticity (in degrees × cm2 × 98 
dmol-1), θ the ellipticity in millidegrees, n is the number of residues of the peptide and c its 99 
molar concentration, d the length of the cell in centimeters.  100 
The mean hydrophobicity (H) and the mean hydrophobic moment (μH) were calculated from 101 
the amino acid sequences, using the Eisenberg scale for hydrophobicity by the HydroMCalc 102 
applet [10] 103 
 104 
Results.  105 
Structural analysis of the peptides. The circular dichroism spectra of peptides in aqueous 106 
solution shows that they are all unstructured in aqueous buffer, with a characteristic minimum 107 
at approximately 200 nm (Figure 1A). With the addition of SDS micelles (Figure 1B), 108 
conformational changes occured in peptides 2 and 5 that are consistent with the formation of 109 
alpha-helix structure with two characteristic minima near 208 and 222 nm. Peptide 1 also 110 
underwent such a transition, although the acquired structure level was lower than the one 111 
seen for peptides 2 and 5. The circular dichroism spectrum of peptide 3 is almost invariable 112 
with the addition of SDS micelles, indicative of the persistence of a disordered conformation. 113 
For omiganan, the spectrum was significantly modified in the presence of SDS, the 200 nm 114 
band was attenuated and a new band near 230 nm appeared; which could be the result of the 115 
interaction between the side chains of tryptophan. Figure 1C shows the helical wheel 116 
projection of the peptides, depicting the amphipatic residues and their relative position in the 117 
alpha helix.   118 
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Peptides were designed in order to have different alpha helical content and different 119 
amphipathicity, the latter calculated as the hydrophobicity and mean hydrophobic moment 120 
with specific software (HydroMCalc and Heliquest). Helical conformation was monitored in SDS 121 
micelles, which are generally employed as a simple membrane-mimetic environment. Table 1 122 
summarizes the structural analyses and hemolytic activity of the peptides.  123 
 124 
Hemolytic activity.  The peptides (C-terminus amidated) were incubated with human red blood 125 
cells in order to evaluate their hemolytic activity. Table 1 shows the results as a relative value 126 
to 100% hemolysis of human red blood cells treated with distilled water.  Peptides 1, 3, 4 and 5 127 
showed little or negligible hemolytic activity, similarly with omiganan. Peptide 2 displayed an 128 
hemolysis of red blood cells almost 4-times higher than omiganan and peptide 5. 129 
 130 
Antimicrobial activity of the peptides. Antimicrobial activity of C-terminus amidated and non 131 
amidated peptides was evaluated by microdilution test against a first panel with 8 isolates. The 132 
panel included 5 clinical (S. warnerii M6823, S. cohnii M6767, S. aureus M6794, P. aeruginosa 133 
M13513 and K. pneumoniae M13540) and 3 ATCC isolates (S. aureus ATCC29213, P. aeruginosa 134 
ATCC27853 and E. coli ATCC25922). MICs values of those peptides with amidated C-terminus 135 
were equal or lower (up to 3 dilutions) than those peptides with non amidated C-terminus, for 136 
the 8 isolates tested (data not shown). Peptide 3, with the lowest hydrophobic moment and 137 
helicity, did not show significant antimicrobial activity, except for coagulase negative 138 
staphylococci (MIC of 8 and 4 mg/L, respectively). Peptide 4 showed no antimicrobial activity 139 
for all the eight isolates tested. On the other hand peptides 1, 2 and 5 showed antimicrobial 140 
activity comparable to, or in some cases better than, omiganan. 141 
Considering these results, together with the lower hemolytic activity of C-terminus amidated 142 
peptides, the antimicrobial activity of the C-terminus amidated peptides 1, 2 and 5 was 143 
evaluated against a large panel of 82 well-characterized bacterial isolates, including the 8 144 
isolates used in the first panel. Table 2 displays MIC values of peptides 1, 2 and 5 and 145 
omiganan against a panel containing 43 gram-negative and 39 gram-positive isolates. This 146 
panel included isolates expressing clinically relevant resistance mechanisms to antibiotics, like 147 
carbapenemase-producing enterobacteria and P. aeruginosa, methicillin-resistant S. aureus or 148 
vancomycin-resistant enterococci (Table 2). Peptide 1 showed MIC90 values of 128 mg/L for all 149 
gram-negative isolates except for K. pneumoniae strains (MIC >1024 mg/L). Peptides 2 and 5 150 
showed similar performance against gram-negative bacteria with MIC90 values between 32 and 151 
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128 mg/L, and slightly lower than peptide 1.  Peptides 1, 2 and 5 showed a similar activity for 152 
each gram-positive species (Table 2). E. faecalis isolates displayed higher MIC values than 153 
other enterococci species for the three analyzed peptides and omiganan (Table 2). No 154 
association between mechanism of resistance and MIC values was observed, similar results 155 
were reported for omiganan by Sader et al. [7]  156 
The omiganan MIC ranges obtained herein were slightly higher (up to three dilutions) than 157 
previous reports [7-8]. Omiganan MIC values for ATCC control strains were into the range 158 
described by Anderegg et al. [13], but on the upper border (Table 2). We suspect that the 159 
difference of our results of MIC range for omiganan could be associated to: i) a smaller number 160 
of isolates included in our panel, ii) our isolates collection could be strongly biased with 161 
antimicrobial resistant strains, and/or iii) intrinsic differences of each population of isolates. 162 
 163 
Concluding remarks. We designed a group of peptides with different physicochemical 164 
characteristics, and tested their antimicrobial activity against a panel of clinical bacterial 165 
isolates. At least seven structural or physical parameters could be considered critical for 166 
biological activity: size, sequence, charge, degree of structuring (helicity), hydrophobicity, 167 
amphipathicity and angles subtended by hydrophobic and hydrophilic faces of the formed 168 
helix [14].  169 
Some authors [15] argue that the secondary structure and biological activity are not coupled, 170 
and AMPs do not form pores in membranes but rather destabilize them disturbing the 171 
organization of the lipids, consistent with the idea that physical chemical and interfacial 172 
properties are the critical factors for determining the biological activity; this theory would suit 173 
omiganan that is not structured as alpha helix. In any case, helicity seems to be an important 174 
parameter for antimicrobial activity in our peptides, since the three peptides that displayed 175 
alpha helical content in SDS micelles also showed antibacterial activity. However, other 176 
parameters may be involved, for example peptide 1 and 5, although having different helicity, 177 
they showed similar antimicrobial activity against Gram-positive strains. But, on the other 178 
hand, these two peptides showed different activity when tested on Gram-negative bacteria, 179 
especially in K. pneumoniae specie (Table 2). 180 
Peptide 2 and 5 had similar physicochemical properties, like alpha helix content, 181 
amphipathicity and net charge, but also antimicrobial activity, however peptide 2 was highly 182 
hemolytic to human red blood cells. Furthermore peptide 1 showed antimicrobial activity 183 
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against gram-positive and -negative strains, although it did not show high alpha helix content 184 
in contact with SDS micelles.   185 
Also interesting was the relative low activity of all these peptides against E. faecalis isolates 186 
(64-256 mg/L), compared to another Enterococci species, like E. faecium and E. gallinarum. 187 
This low activity was also observed for omiganan [7], indicating a possible different cell wall 188 
composition in E. faecalis specie. It is evident that certain differences within the bacterial cell 189 
wall are probably associated with these different sensitivities to AMPs.  190 
Peptides 1, 2 and 5 showed good antibacterial activity against a broad spectrum of clinical 191 
isolates, although peptide 2 displayed high cytotoxicity. These three peptides could become 192 
good templates for topical use. 193 
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Figure 1. Graphical analysis of the peptides structure. 200 
Footnote: Circular dichroism of peptides in aqueous solution (panel A) and in SDS micelles (panel B). Helical wheel 201 
projection diagrams of the peptides, considering the first 18 amino acids (panel C). omi, omiganan; p1, peptide 1; 202 
p2, peptide 2; p3, peptide 3; p5, peptide 5.  203 
 204 
 205 
Table 1. Physicochemical properties, structural analyses and hemolytic activity of the peptides 206 
Footnote: The values for hydrophobicity (H) and mean hydrophobic moment (μH) were obtained from HydroMCalc 207 
software.  The percent helix values were determined based on circular dichroism spectra calculated as the mean 208 
residue molar ellipticity at 222 nm, in SDS micelles.  * Isolelectric point and net charge were calculated for the acidic 209 
C terminus version of the peptides. Hemolytic activity is shown as a percentage (%) of hemolysis compared to 210 
distilled water (100% hemolysis). One representative experiment. Ne: not evaluated 211 
 212 
Table 2. Antimicrobial activity of three designed peptides and omiganan against gram-negative 213 
and gram-positive bacteria. 214 
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Table 1.
Peptide 1 Peptide 2 Peptide 3 Peptide 4 Peptide 5
Mean Hydrophobicity (H ) -0.67 -0.23 -0.54 -0.12 -0.28
Mean hydrophobic moment (µH ) 0.24 0.35 0.14 0.17 0.41
Helicity (%Helix) 27.86 64.2 0.54 8.81 88.43
*Isoelectric Point 13.10 10.89 12.25 9.85 11.75
*Net Charge +12 +6 +7 +3 +7
Hemolytic activity 3.4 39.8 1.5 1.72 9.5
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Omiganan
-0.31
0.28
10.15
12.79
+4
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Peptide 1 Peptide 2 Peptide 5 Omiganan
M5306
bla PER-2 + bla CTX-M-2 + 
blaTEM-1 
256 4 64 64
M9209 bla KPC-2 128 64 128 64
S. aureus (11)
ATCC29213 none 32 64 32 32
P33 msrA 32 128 64 32
P28 ermA 32 64 64 32
P204 ermA 64 64 32 64
M6276 ermA + lnuA 16 128 64 32
P239 ermC 32 64 64 32
M6794 mecA 32 64 64 64
M2832 mecA 32 128 64 64
M4046 mecA 32 128 32 32
M6820 mecA 64 128 64 128
M6784 mecA 32 32 32 32
S. epidermidis (4)
M2923 none 16 16 16 8
M2931 none 16 16 8 16
M2919 mecA 16 16 8 8
M2921 mecA 8 8 8 8
S. saprophyticus (2)
M4070 mecA 16 32 8 8
M2981 mecA 16 8 8 8
S. haemolyticus (2)
M2976 mecA 16 8 8 4
M3014 none 16 8 8 4
S. hominis (2)
M2973 mecA 4 4 4 4
M2967 mecA 8 8 8 4
S. warnerii (1)
M6823 mecA 8 8 8 8
S. cohnii (1)
M6767 mecA 16 16 8 4
E. faecalis (8)
ATCC 29212 none 64 128 128 128
ATCC 51299 vanB 256 256 256 256
M4899 vanB 256 128 256 256
M6534 vanB 128 256 256 256
M4992 vanA 128 128 128 128
M6383 vanA 128 128 128 128
M4449 vanA 128 128 128 128
M6983 vanA 64 128 128 128
E. faecium (6)
PZAP95 none 32 16 16 16
M6261 none 32 16 16 16
M2619 vanB 32 16 16 16
M2481 vanB 32 16 16 16
M2304 vanA 16 16 8 4
M2664 vanA 16 8 8 8
E. gallinarum (2)
M2723 vanC1 + vanA 32 32 16 16
M2685 vanC1 + vanA 16 16 16 16
Table 2 continued,
Specie Strain Genes
MIC (mg/L)
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Peptide 1 Peptide 2 Peptide 5 Omiganan
P. aeruginosa (12)
ATCC 27853 none 64 64 64 256
PCOS12 none 64 64 64 512
M5470 none 128 64 64 512
M7907 bla PER 128 64 64 128
M13513 bla KPC-2 32 64 64 256
M11005 bla KPC-2 64 64 128 512
M7723 bla KPC-2 64 64 32 256
M7728 bla IMP 128 64 64 512
M5109 bla VIM + blaGES-1 128 64 64 256
M5200 bla VIM + blaGES-1 64 64 64 512
M7525 bla SPM 64 64 64 512
M7712 bla SPM 64 64 64 512
Acinetobacter sp. (10)
M13523 bla OXA-51 64 4 64 32
M9665 bla OXA-51 128 32 128 4
M5282 bla OXA-51 64 8 64 8
M5179 bla OXA-51 64 32 64 32
M7489 bla OXA-51 + bla TEM 64 16 64 8
PFAV1
bla OXA-51 +  blaOXA-58 + 
blaPER
64 16 64 16
M5277 bla PER 64 8 64 32
M5949 bla OXA-23 + bla OXA-GVI 256 16 256 32
M7978 bla IMP-1 64 8 64 16
M9013 bla OXA-51 + bla IMP 32 8 32 32
K. pneumoniae (12)
PFAV3 none 1024 128 128 128
M9140 bla CIT 1024 32 32 64
M9491 bla MOX 1024 64 64 128
M9170 bla OXA-GIII >1024 32 64 128
M5825 bla GES-3 + bla CTX-M-2 >1024 8 32 64
M9310
bla CTX-M-2 + blaTEM-1 + 
blaSHV-1
>1024 16 32 64
M9375
bla CTX-M-2 + blaTEM-1 + 
blaSHV-1
1024 64 16 32
M1803
bla PER-2 + bla CTX-M-2 + 
blaTEM-1 + blaSHV + 
bla OXA-9 
>1024 32 64 1024
M7647
bla VIM + bla CTX-M-2 + 
blaTEM-1 + blaSHV-1 
>1024 32 32 1024
M13540 bla KPC-2 >1024 16 64 256
M9885 bla KPC-2 >1024 64 32 256
M11245 bla KPC-2 + bla PER-2 1024 16 8 32
E. coli (9)
ATCC 25922 none 128 32 32 64
M9884 none 128 32 32 64
M7859 bla CIT 128 32 16 64
PNEU23 bla OXA-GIII + bla TEM-1 128 32 32 32
PCOS15 bla PER-2 + blaTEM-1 128 64 64 64
PABC11 bla CTX-M-2 128 32 32 64
PLCA1 bla CTX-M-2 + blaTEM-1 128 64 64 64
Table 2. 
Specie Strain Genes
MIC (mg/L)
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M5306
bla PER-2 + bla CTX-M-2 + 
blaTEM-1 
256 4 64 64
M9209 bla KPC-2 128 64 128 64
S. aureus (11)
ATCC29213 none 32 64 32 32
P33 msrA 32 128 64 32
P28 ermA 32 64 64 32
P204 ermA 64 64 32 64
M6276 ermA + lnuA 16 128 64 32
P239 ermC 32 64 64 32
M6794 mecA 32 64 64 64
M2832 mecA 32 128 64 64
M4046 mecA 32 128 32 32
M6820 mecA 64 128 64 128
M6784 mecA 32 32 32 32
S. epidermidis (4)
M2923 none 16 16 16 8
M2931 none 16 16 8 16
M2919 mecA 16 16 8 8
M2921 mecA 8 8 8 8
S. saprophyticus (2)
M4070 mecA 16 32 8 8
M2981 mecA 16 8 8 8
S. haemolyticus (2)
M2976 mecA 16 8 8 4
M3014 none 16 8 8 4
S. hominis (2)
M2973 mecA 4 4 4 4
M2967 mecA 8 8 8 4
S. warnerii (1)
M6823 mecA 8 8 8 8
S. cohnii (1)
M6767 mecA 16 16 8 4
E. faecalis (8)
ATCC 29212 none 64 128 128 128
ATCC 51299 vanB 256 256 256 256
M4899 vanB 256 128 256 256
M6534 vanB 128 256 256 256
M4992 vanA 128 128 128 128
M6383 vanA 128 128 128 128
M4449 vanA 128 128 128 128
M6983 vanA 64 128 128 128
E. faecium (6)
PZAP95 none 32 16 16 16
M6261 none 32 16 16 16
M2619 vanB 32 16 16 16
M2481 vanB 32 16 16 16
M2304 vanA 16 16 8 4
M2664 vanA 16 8 8 8
E. gallinarum (2)
M2723 vanC1 + vanA 32 32 16 16
M2685 vanC1 + vanA 16 16 16 16
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Circular  dichroism of  peptides  in  aqueous  solution  (panel  A)  and  in  SDS  micelles  (panel  B). 
Projection of helical wheel of the peptides (panel C). omi, omiganan; p1, peptide 1; p2, peptide 2; 
p3, peptide 3; p4, peptide 4; p5, peptide 5.
Figure 1.
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Antimicrobial activity of de novo designed cationic peptides 
against multi-resistant clinical isolates. 
 
Highlights. 
- de novo designed cationic peptides 
- physicochemical properties of peptides 
- antimicrobial resistant bacteria 
 
